Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Impact of conditioning regimen on outcomes of adolescents and young adults AML patients undergoing HCT in complete remission, with transplant conditioning intensity score of 3.5-4.0. a study from the acute leukemia working party of the european society for blood and marrow transplantation.

View Full Paper
Ask AI
Bookmark
Share

Authors

MAMahmoud AljurfRLRégis Peffault de LatourIBIgor Wolfgang Blau

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows that high-dose TBI-free regimens improve survival in adolescents and young adults with AML, indicating a shift in transplant practices.

Key Points

  • To assess the impact of different myeloablative conditioning regimens on outcomes of AYA patients with AML undergoing HCT.
  • Retrospective analysis of AML patients aged 18-40 years in complete remission at the time of HCT.
  • Comparison of outcomes across four conditioning regimens: TBI-based, TBF, Bu-Flu, and Bu-Cy.
  • Outcomes assessed included overall survival, progression-free survival, disease relapse, and non-relapse mortality.
  • Two-year overall survival rates were highest for TBF (81.2%) followed by Bu-Flu (74.4%).
  • Progression-free survival rates showed a similar pattern, with TBF significantly improving outcomes compared to other regimens.
  • Bu-Flu and TBF regimens were associated with lower risks of disease relapse and non-relapse mortality.

Cite This Study

Aljurf et al. (2025) studied this question.

synapsesocial.com/papers/693624d44fa91c937236cffehttps://doi.org/10.1182/blood-2025-112
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1An evolving landscape – how changing conditioning regimes can improve myelofibrosis transplant outcomes.2025
  2. 2Conditioning intensity and post-transplant outcomes in acute myeloid leukemia: A real-world analysis.2026
  3. 3Impact of thiotepa dose in haploidentical allogeneic stem cell transplantation with thiotepa-busulfan-fludarabine conditioning for Acute Myeloid Leukemia in remission: A retrospective analysis of the EBMT acute leukemia working party2025
  4. 4Myeloablative fractionated busulfan, fludarabine, cladribine, thiotepa, and venetoclax (Cladillac) conditioning for high-risk AML: A phase 2 trial2025
  5. 5Allogeneic hematopoietic stem cell transplantation for hematological malignancies using nonmyeloablative fludarabine, cyclophosphamide, 200 centigray total body irradiation, and post-transplant cyclophosphamide, sirolimus, and mycophenolate mofetil for graft-versus-host disease prophylaxis is associated with low non-relapse mortality.2025